LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    EuropaBio National Associations Council Summit 2022 (French Presidency): how does biotechnology deliver the Industrial strategy across sectors?

    01/02/2022
    NEWS RELEASE
    EuropaBio and members France Biotech, MabDesign and Bioeconomy for Change are delighted to invite delegates to the second National Associations Council Summit 2022, being hosted during the Council Presidency of France. ‘Biotechnology: Delivering Europe’s industrial strategy across sectors’ will take place on 3 March 2022, 10:00-13.30 CET online.

    National Associations, biotech companies of all sizes, policy makers and others will discuss the commercial pathways for healthcare biotechnology to deliver innovative therapeutics to patients, and for industrial biotechnology to drive economic growth and market development.

    ’Europe is showing right now, how to be competitive as a result of innovative advances in Member states. We are a leader in Research and Development and Innovation, and this has to translate rapidly into contributions towards Europe’s industrial strategy. For the second year, our National Associations Council Summit invites members and stakeholders to address healthcare and industrial biotechnology priorities in the light of the Agenda of the French Presidency of the Council of the EU. European and national performance is intertwined, and the policies that drive biotechnology have to work across European countries’’, said Dr Claire Skentelbery, Director General of EuropaBio.

    The Summit will be divided into two parts: Healthcare biotechnology: Innovative therapeutics to patients in Europe; and Industrial biotechnology and bioeconomy: Growth and innovation to market.

    The Healthcare biotechnology panel addresses how we transform research to sustainable and accessible healthcare. Speakers and participants will discuss national and EU initiatives, and policies, that help move research advances through to patient uptake. Critically, how we create momentum and investment into technologies, skills and infrastructure for next generation therapies in Europe, and how Europe can enable cross-border healthcare delivering benefit for European citizens.

    The second part of the Summit will be devoted to Industrial biotechnology and bioeconomy and its growth and innovation to market. The panel will discuss initiatives and policies that enable long term investment into largescale manufacture and ensuring a competitive next generation industrial landscape. Finally, the discussion will include novel foods and their role in Europe’s future sustainability and competitiveness, with the critical policy and regulatory framework that enables investment.

    Register to the Summit here.

    Highlights from the National Associations Council Summit 2021 (Portugal) here.

    EuropaBio National Associations Council Summit 2022 (French Presidency): how does biotechnology deliver the Industrial strategy across sectors?


    Download
    Share
    Communications Team
    Communications Team

    Related posts

    18/05/2026

    Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force


    Read more
    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.